LGI1 and epilepsy: After symptom control, immunotherapies could be discontinued without early deteriorations, regardless of titers (NMDAR-6, LGI1-1, -3, -5, -7 [epilepsy persisted], -8, -9, 10, CASPR2-1, -4 [epilepsy persisted],-5, -6; two of these patients relapsed after > 1 year: NMDAR-6; LGI1-9).